Methods
|
Penicillin G %
|
Ciprofloxacin %
|
Ceftriaxone %
|
Tetracycline %
|
Spectinomycin %
|
Azithromycin %
|
---|
|
S
|
I
|
R
|
S
|
I
|
R
|
S
|
I
|
R
|
S
|
I
|
R
|
S
|
I
|
R
|
S
|
I
|
R
|
---|
Etest MIC
|
08
|
49
|
43
|
00
|
14
|
86
|
100
|
00
|
00
|
12
|
37
|
51
|
100
|
00
|
00
|
99
|
00
|
01
|
CLSI/BSACa MIC break points (μg/ml)
|
≤0.06
|
0.12-1
|
≥2
|
≤0.06
|
0.12-0.5
|
≥1
|
≤0.25
|
-
|
-
|
≤0.25
|
0.5–1
|
≥2
|
≤32
|
64
|
≥128
|
≤0.25
|
0.5
|
≥0.5
|
CDS disc diffusion
|
10
|
13
|
77
|
00
|
20
|
80
|
100
|
00
|
00
|
NP
|
NP
|
NP
|
100
|
00
|
00
|
99
|
00
|
01
|
CDS annular radius break points (mm)
|
>9
|
3-9
|
<3
|
≥11
|
6-10
|
<6
|
≥10
|
-
|
5-9
|
NP
|
NP
|
NP
|
≥6
|
-
|
<6
|
≥8
|
-
|
<8
|
CLSI disc diffusion
|
04
|
34
|
62
|
00
|
04
|
96
|
100
|
00
|
00
|
03
|
40
|
57
|
100
|
00
|
00
|
99
|
00
|
01
|
CLSI/BSACa zone diameter break points (mm)
|
≥47
|
27-46
|
≤26
|
>41
|
28-40
|
≤27
|
≥35
|
-
|
-
|
≥38
|
31-37
|
<30
|
≥18
|
15-17
|
≤4
|
≥28
|
-
|
≤27
|
-
S sensitive, I intermediate, R resistant
-
NP not performed
-
aBSAC breakpoints were used for Azithromycin